文献速递产科母胎医学

接受妊娠期糖尿病筛查个体中的持续葡萄糖监测

Continuous glucose monitoring in individuals undergoing gestational diabetes screening.
PubMed 文献 · Am J Obstet Gynecol · 2023-04-23

这项前瞻性研究纳入≤30周接受两步法妊娠期糖尿病筛查的个体,佩戴盲法持续葡萄糖监测设备10天。持续葡萄糖监测显示高于目标范围时间≥10%的个体,其新生儿复合不良结局发生率显著高于<10%者(63% vs 18%,P=.001)。作者认为该阈值与新生儿不良结局较高发生率相关,一项持续葡萄糖监测对比两步法筛查的随机试验正在进行中。

要点

  • 持续葡萄糖监测高于目标范围时间≥10%者新生儿复合不良结局发生率为63%,<10%者为18%(P=.001)。
  • 高于目标范围时间≥10%者新生儿低血糖发生率为47%,<10%者为14.5%(P=.009)。
  • 高于目标范围时间≥10%者新生儿住院时间4天,<10%者为2天(P=.03)。

核心结论

  • 在接受妊娠期糖尿病筛查的个体中,持续葡萄糖监测高于目标范围时间≥10%与新生儿不良结局发生率较高相关。
  • 一项持续葡萄糖监测对比两步法妊娠期糖尿病筛查以降低不良结局发生率的随机试验正在进行中(注册号:NCT05430204)。

研究设计与样本

  • 前瞻性研究,时间范围为2020年6月至2022年1月。
  • 研究对象为在≤30周妊娠时接受两步法妊娠期糖尿病筛查的个体。
  • 参与者从接受50克葡萄糖挑战试验时起佩戴盲法持续葡萄糖监测设备(Dexcom G6 Pro;Dexcom, Inc, San Diego, CA)10天。
  • 共招募136名参与者,其中92名(67.6%)有可用数据。
  • 两步法诊断妊娠期糖尿病2例(2.2%)。

主要发现

  • 持续葡萄糖监测显示17名个体(18.5%)高于目标范围时间≥10%。
  • 高于目标范围时间≥10%者新生儿复合不良结局发生率为63%,<10%者为18%(P=.001)。
  • 高于目标范围时间≥10%者新生儿低血糖发生率为47%,<10%者为14.5%(P=.009)。
  • 高于目标范围时间≥10%者新生儿住院时间为4天,<10%者为2天(P=.03)。
  • 两组间母体结局未见差异。

关键数值与推荐

  • 目标范围为63-140 mg/dL,高于目标范围为>140 mg/dL,以占全部持续葡萄糖监测读数的百分比表示。
  • 采用约登指数选择高于目标范围时间≥10%作为阈值。
  • 主要结局为新生儿不良结局复合指标:大于胎龄儿、肩难产或新生儿损伤、呼吸窘迫、低血糖需静脉葡萄糖治疗、或胎儿或新生儿死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Among guidelines on gestational diabetes mellitus, there is an incongruity about the threshold of maternal hyperglycemia to diagnose gestational diabetes mellitus. OBJECTIVE: This study aimed to ascertain the association between continuous glucose monitoring metrics and adverse outcomes among individuals undergoing gestational diabetes mellitus screening. STUDY DESIGN: This was a prospective study (from June 2020 to January 2022) of individuals who underwent 2-step gestational diabetes mellitus screening at ≤30 weeks of gestation. The participants wore a blinded continuous glucose monitoring device (Dexcom G6 Pro; Dexcom, Inc, San Diego, CA) for 10 days starting when they took the 50-g glucose challenge test. The primary outcome was a composite of adverse neonatal outcomes (large for gestational age, shoulder dystocia or neonatal injury, respiratory distress, need for intravenous glucose treatment for hypoglycemia, or fetal or neonatal death). The secondary neonatal outcomes included preterm birth, neonatal intensive care unit admission, hypoglycemia, mechanical ventilation or continuous positive airway pressure, hyperbilirubinemia, and hospital length of stay. The secondary maternal outcomes included weight gain during pregnancy, hypertensive disorders of pregnancy, induction of labor, cesarean delivery, and postpartum complications. Time within the target range (63-140 mg/dL), time above the target range (>140 mg/dL) expressed as a percentage of all continuous glucose monitoring readings, and mean glucose level were analyzed. The Youden index was used to choose the threshold of ≥10% for the time above the target range and association with adverse outcomes. RESULTS: Of 136 participants recruited, data were available from 92 individuals (67.6%). The 2-step method diagnosed gestational diabetes mellitus in 2 individuals (2.2%). Continuous glucose monitoring indicated that 17 individuals (18.5%) had time above the target range of ≥10%. Individuals with time above the target range of ≥10% had a significantly higher likelihood of composite adverse neonatal outcomes than individuals with time above the target range of <10% (63% vs 18%; P=.001). Furthermore, compared with neonates born to individuals with time above the target range of <10%, neonates born to individuals with time above the target range of ≥10% had an increased likelihood for hypoglycemia (14.5% vs 47%; P=.009) and had a longer length of stay (2 vs 4 days; P=.03). No difference in maternal outcomes was noted between the groups. CONCLUSION: In this prospective study of individuals undergoing gestational diabetes mellitus screening, a cutoff of the time above the target range of ≥10% using continuous glucose monitoring was associated with a higher rate of neonatal adverse outcomes. A randomized trial of continuous glucose monitoring vs 2-step screening for gestational diabetes mellitus to lower the rate of adverse outcomes is underway (identification number: NCT05430204).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Fishel Bartal M, Ashby Cornthwaite J, Ghafir D, et al. Continuous glucose monitoring in individuals undergoing gestational diabetes screening. Am J Obstet Gynecol. 2023. PMID: 37088275. doi:10.1016/j.ajog.2023.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。